Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands

British Journal of Cancer

Volumn 94, Issue 1, 2006, Pages 171-175

  Bulk, S ^a   Berkhof, J ^a   Bulkmans, N W J ^a   Zielinski, G D ^a   Rozendaal, L ^a   Van Kemenade, F J ^a   Snijders, P J F ^a   Meijer, C J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinoma; Cervix neoplasm; Cohort study; Epidemiology; Human papillomavirus; Squamous cell carcinoma

Indexed keywords

ADENOCARCINOMA; ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CARCINOMA IN SITU; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FREQUENCY ANALYSIS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VIRUS STRAIN; VIRUS TYPING;

ADENOCARCINOMA; ADOLESCENT; ADULT; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 30644469798     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602915     Document Type: Article

References (26)

1. Altekruse SF, Lacey Jr JV, Brinton LA, Gravitt PE, Silverberg SG, Barnes Jr WA, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Hildesheim A (2003) Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol 188: 657-663
2. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ (2005) Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer 115: 268-275
3. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ (2004) The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 57: 388-393
4. Bulkmans NW, Bleeker MC, Berkhof J, Voorhorst FJ, Snijders PJ, Meijer CJ (2005) Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 117: 177-181
5. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, van den Brule AJ, Meijer CJ (2004) POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 110: 94-101
6. Burk RD, Terai M, Gravitt PE, Brinton LA, Kurman RJ, Barnes WA, Greenberg MD, Hadjimichael OC, Fu L, McGowan L, Mortel R, Schwartz PE, Hildesheim A (2003) Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res 63: 7215-7220
7. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD (2005a) A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191: 1808-1816
8. Castle PE, Solomon D, Schiffman M, Wheeler CM (2005b) Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97: 1066-1071
9. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM (2005) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14: 1157-1164
10. Clifford GM, Smith JS, Aguado T, Franceschi S (2003a) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89: 101-105
11. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003b) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73
12. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P (2003) Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362: 1871-1876
13. Huang LW, Chao SL, Chen PH, Chou HP (2004) Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. J Clin Virol 29: 271-276
14. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM (1997) A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35: 791-795
15. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072-1079
16. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527
17. Pilch H, Gunzel S, Schaffer U, Tanner B, Brockerhoff P, Maeurer M, Hockel M, Hommel G, Knapstein PG (2001) The presence of HPV DNA in cervical cancer: correlation with clinico-pathologic parameters and prognostic significance: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 11: 39-48
18. Schwartz SM, Daling JR, Shera KA, Madeleine MM, McKnight B, Galloway DA, Porter PL, McDougall JK (2001) Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol 19: 1906-1915
19. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright Jr T, Young N (2002) The 2001 bethesda system: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119
20. van Ballegooijen M, Hermens R (2000) Cervical cancer screening in the Netherlands. Eur J Cancer 36: 2244-2246
21. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ (2002) GP5+/6+ PCR followed by Reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40: 779-787
22. van Oortmarssen GJ, Habbema JD (1995) Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol 24: 300-307
23. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19
24. Woodman CB, Collins S, Rollason TP, Winter H, Bailey A, Yates M, Young LS (2003) Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 361: 40-43
25. Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, Jiwa NM, van der Linden HC, de Schipper FA, Runsink AP, Meijer CJ (2003) The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 201: 535-543
26. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, van der Linden HC, Runsink AP, de Schipper FA, Meijer CJ (2001) HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 85: 398-404